RxDoctor Payments Data

Sandra Cremers, MD

Ophthalmology · Boston, MANPI 1588654040

Payments from drug & device makers

$6,077in general payments, 2019–2025

Across 235 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$1K
  • AbbVie$851
  • Alcon$693
  • NEW World Medical,inc.$405
  • Rxsight Inc$288
  • Oyster Point Pharma, Inc.$282
  • plus $2K from 28 others

What the payments were for

  • Food & beverage$5,70594%
  • Education$3726%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,077 in reported general payments places this provider in the 80th percentile of 653 ophthalmology providers in Massachusetts.

See all ophthalmology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$178,349
Medicare patients
352
Services billed
1,298

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast143$194,124
RestasisCyclosporine42$68,662
MieboPerfluorohexyloctane/Pf51$39,200
LumiganBimatoprost23$12,249
SimbrinzaBrinzolamide/Brimonidine Tart21$8,203
Cyclosporine11$5,320
Prednisolone Acetate56$2,478
Loteprednol Etabonate13$2,467
ValacyclovirValacyclovir Hcl13$2,226
Doxycycline Hyclate88$1,771
Brimonidine Tartrate54$1,298
Latanoprost74$931
Bacitracin11$831
Ketorolac Tromethamine37$760
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha44$405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$86$233,324194 claims
AbbVieRestasis, Lumigan$851$80,91165 claims
AlconSimbrinza$693$8,20321 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$30$2,46713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 653 ophthalmology providers in Massachusetts.

Other ophthalmology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →